EMBARK: Overall survival with enzalutamide in biochemically recurrent #ProstateCancer Presented at #ESMO25 https://t.co/AGD25siONA Enzalutamide plus leuprolide significantly improves overall survival and delays disease progression compared with leuprolide alone in high-risk

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study out on Annals of Oncology https://t.co/uUnQ6N6A13 CAPItello-281 In PTEN-deficient metastatic hormone-sensitive #ProstateCancer , adding the AKT inhibitor

The mHSPC space becomes more and more interesting! Come and participate in the discussions @APCCC_Lugano register via https://t.co/fPN1UjMfsX!

Men with PSA <1–2 ng/ml at 60 are very unlikely to die from prostate cancer. Screening them again may just cause harm, not help. #ProstateCancer @JNCI_Now @APCCC_Lugano @PCFnews https://t.co/ky2BoM6HJz

Don’t miss to take a look in our poster at #ESMO25 . Evaluation of the types of systemic treatments as well as the associated costs in >30k mCRPC patients in the Brazilian public health system. @myESMO @SoaresAndrey @APCCC_Lugano @Silke_Gillessen

🚨 Big News from #APCCC26 🚨 APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! Full details & submission 👉 https://t.co/U46NMslfll 📅 Key Dates: 🔹 Submission opens: 1 Sept

Rectal Swab–based Targeted Prophylactic Antibiotics Reduce Infectious Complications After Transrectal Prostate Biopsy https://t.co/Sli3AptJrb In this systematic review and meta-analysis of nine randomized controlled trials including 3,002 patients, the use of targeted

Another important topic for @APCCC_Lugano! Come and join us, registration is open via https://t.co/fPN1UjMfsX and deadline for abstract submission is close!

Dear #ESMO25 Big News from #APCCC26 🚨APCCC is opening a Call for Abstracts! 👉 https://t.co/m1lKsEhhwS Here are @Silke_Gillessen & @AOmlin to tell you why the discussions here in Berlin will be so relevant for APCCC in Lugano 🇨🇭 @APCCC_Lugano Creating new opportunities for

Dear Colleagues at #ESMO25 An honor to present our faculty🚨 @Silke_Gillessen and @AOmlin straight from Berlin who discuss about: The Radioligand Therapy Session on #ProstateCancer VERY hot Topics and some that will spark up conversation in Lugano🇨🇭 for #APCCC26 @APCCC_Lugano

Dear #ESMO25 Big News from #APCCC26 🚨APCCC is opening a Call for Abstracts! ❓ SUBMIT YOUR QUESTION👉 https://t.co/dJKiWbkrOr ⭐ Full details & submission 👉 https://t.co/m1lKsEhhwS Creating new opportunities for younger investigators & the next generation of leaders in

Dear #ESMO25 Big News from #APCCC26 🚨APCCC is opening a Call for Abstracts! SUBMIT YOUR QUESTION👉 https://t.co/dJKiWbkrOr ⭐ Full details & submission 👉 https://t.co/m1lKsEhhwS Creating new opportunities for younger investigators & the next generation of leaders in

Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapy https://t.co/RUDzysly4x This multicenter retrospective study of 214 patients with metastatic castration-resistant #ProstateCancer (mCRPC) treated with

Dear colleagues at #ESMO25 Big News from #APCCC26 🚨APCCC is opening a Call for Abstracts! Full details & submission 👉 https://t.co/m1lKsEhhwS Creating new opportunities for younger investigators & the next generation of leaders in advanced #ProstateCancer @Silke_Gillessen &

Combined SNPs sequencing and allele specific proteomics capture reveal functional causality underpinning the 2p25 prostate cancer susceptibility locus https://t.co/Xe1d5ifbtM This study identifies and functionally characterizes rs4519489, a #ProstateCancer –associated SNP

#EMBARK didn’t write the book📕on #BCR📈#ProstateCancer-it is merely the first chapter What do #BCR trials look like in the #PSMA🩻era? 30+experts met @theNCI🏛️ to provide a roadmap🧭 @JCO_ASCO @ASCO @PCF_Science @APCCC_Lugano @urotoday https://t.co/ePbf8j7KQU

Finally Managed to gather a fantastic bunch of KOLs from India 🇮🇳 Bangladesh Sri Lanka and Nepal. Discussed the nuances of PCa Mx. Plenty of friendly banter and leg pulling. Official APCCC South Asia. Paper with similarities yet differences from @APCCC_Lugano coming soon.

PRIME trial: Biparametric MRI (no contrast) caught significant prostate cancer as well as full multiparametric scans. Shorter, cheaper, safer, could reset the standard of care worldwide? #ProstateCancer #Oncology doi:10.1001/jama.2025.13722 @JAMA_current @APCCC_Lugano @PCFnews

💫🌟🎓 Dana-Farber | Aggressive #ProstateCancer 🧬 @MikeSerzanMD @OncoAlert @APCCC_Lugano New treatment advances improving outcomes: ➡️ PARP inhibitors – esp. in BRCA1/2-mutated PCa ➡️ Radioligand therapy (Pluvicto earlier use, combos w/ Act-225) ➡️ Immunotherapy – bispecific